China Pharma Holdings Inc CPHI Stock Analysis
- NYSE American
- Stock
- Market closed · opens Monday 9:30 AM ET
$0.57 up $0.04, 7.53% at close Nov 6
Last close · Previous close $0.53
- Market cap
- $23.09MAt the Nov 6 close
- P/E ratio
- PausedOn last 12 months’ EPS
See the note under the price. - Diluted EPS
- PausedLast 12 months
See the note under the price. - Dividend yield
- NoneLast 12 months
Price chart
$0.57down $0.07, 11.11%Past month
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$0.53Nov 5
- Volume41.45KNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume332.34KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $0.38 to $19.19; now $0.57
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
CPHI trailed the S&P 500 in all 7 periods.
| Period | CPHI and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | CPHI: down 11.1% S&P 500: down 5.6% | CPHI trailed the S&P 500 by 5.5 percentage points Trailed |
| 3M | CPHI: down 52.9% S&P 500: down 4.1% | CPHI trailed the S&P 500 by 48.8 percentage points Trailed |
| YTD | CPHI: down 52.9% S&P 500: up 8.7% | CPHI trailed the S&P 500 by 61.6 percentage points Trailed |
| 1Y | CPHI: down 64.5% S&P 500: up 10.9% | CPHI trailed the S&P 500 by 75.4 percentage points Trailed |
| Long term | ||
| 3Y | CPHI: down 89.0% S&P 500: up 75.0% −52.1% vs +20.5% a year | CPHI trailed the S&P 500 by 164.0 percentage points Trailed |
| 5Y | CPHI: down 99.8% S&P 500: up 67.8% −71.6% vs +10.9% a year | CPHI trailed the S&P 500 by 167.6 percentage points Trailed |
| 10Y | CPHI: down 99.4% S&P 500: up 313.1% −40.3% vs +15.2% a year | CPHI trailed the S&P 500 by 412.5 percentage points Trailed |
$10,000 invested in CPHI 10 years ago (Nov 4, 2016) would be worth about $57 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
CPHI trailed the S&P 500 in all 7 periods.
| Period | CPHI and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | CPHI: down 11.1% S&P 500: down 5.6% | CPHI trailed the S&P 500 by 5.5 percentage points Trailed |
| 3M | CPHI: down 52.9% S&P 500: down 4.3% | CPHI trailed the S&P 500 by 48.6 percentage points Trailed |
| YTD | CPHI: down 52.9% S&P 500: up 7.8% | CPHI trailed the S&P 500 by 60.7 percentage points Trailed |
| 1Y | CPHI: down 64.5% S&P 500: up 9.7% | CPHI trailed the S&P 500 by 74.2 percentage points Trailed |
| Long term | ||
| 3Y | CPHI: down 89.0% S&P 500: up 68.8% −52.1% vs +19.1% a year | CPHI trailed the S&P 500 by 157.8 percentage points Trailed |
| 5Y | CPHI: down 99.8% S&P 500: up 56.9% −71.6% vs +9.4% a year | CPHI trailed the S&P 500 by 156.7 percentage points Trailed |
| 10Y | CPHI: down 99.4% S&P 500: up 252.6% −40.3% vs +13.4% a year | CPHI trailed the S&P 500 by 352.0 percentage points Trailed |
$10,000 invested in CPHI 10 years ago (Nov 4, 2016) would be worth about $57 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$18,800.00
Closing high on . Now 100.0% below that record.
Split-adjusted daily closes since Apr 17, 2002.
Stock splits
4
Latest: 1-for-10 on . Share counts adjust after each split.
All 4 splits
- 1-for-10
- 1-for-5
- 1-for-10
- 1-for-20
Valuation
The Nov 6 close compared with the last 12 months of reported results (the four quarters to Jun 30, 2026). Tap a metric to see how it’s calculated. Per-share results and the measures based on them are paused. See the note under the price.
Price-to-earnings (P/E)
Paused
Other valuation measures
- 5.9×Last 12 months’ revenue
Market value divided by revenue over the last 12 months. Useful when earnings are small or negative.
P/S = Market cap ÷ Revenue (last 12 months)Price-to-sales ratio - Price-to-bookPausedBook value as of Jun 30, 2026
See the note under the price. - PEG ratioPausedLast 12 months’ EPS growth
See the note under the price. - −0.75%Last 12 months’ free cash flow
Free cash flow over the last 12 months as a share of the company’s market value: the cash the business generated for each dollar of stock.
FCF yield = Free cash flow (last 12 months) ÷ Market capFree cash flow - $26.54MAt the Nov 6 close
What it would cost to buy the whole business: the market cap at the Nov 6 close, plus debt, minus cash and short-term investments from the Jun 30, 2026 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own CPHI DCF in Excel. Value China Pharma Holdings with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $3.91Mdown 11.0%
- Net income
- −$4.47M
- Diluted EPS
- PausedSee the note under the price.
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $1.10M | −$1.12M | Paused See the note under the price. |
| Q4 FY24 (Dec 31, 2024) | $1.13M | −$1.22M | Paused See the note under the price. |
| Q1 FY25 (Mar 31, 2025) | $1.14M | −$785.57K | Paused See the note under the price. |
| Q2 FY25 (Jun 30, 2025) | $1.03M | −$528.37K | Paused See the note under the price. |
| Q3 FY25 (Sep 30, 2025) | $756.22K | −$651.48K | Paused See the note under the price. |
| Q4 FY25 (Dec 31, 2025) | $1.23M | −$1.22M | Paused See the note under the price. |
| Q1 FY26 (Mar 31, 2026) | $983.54K | −$1.14M | Paused See the note under the price. |
| Q2 FY26 (Jun 30, 2026) | $948.34K | −$1.46M | Paused See the note under the price. |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $9.64M | −$3.40M | Paused See the note under the price. |
| FY22 (Dec 31, 2022) | $8.10M | −$3.97M | Paused See the note under the price. |
| FY23 (Dec 31, 2023) | $7.01M | −$3.08M | Paused See the note under the price. |
| FY24 (Dec 31, 2024) | $4.53M | −$4.74M | Paused See the note under the price. |
| FY25 (Dec 31, 2025) | $4.14M | −$3.19M | Paused See the note under the price. |
Margins
- Gross 11.8%
- Operating −111.8%
- Net −114.3%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$174.18KLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$173.12KLast 12 months
- Capital spending$1.07KLast 12 months
- −4.5%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $0.00Last 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $304.87KAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$3.75MAs of Jun 30, 2026
- Net debt$3.45MAs of Jun 30, 2026
- Book value per sharePausedAs of Jun 30, 2026
See the note under the price. - 0.26As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.10As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 3 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✗Net income was positive: not passed
- ✗Operating cash flow was positive: not passed
- ✗Return on assets improved: not passed
- ✓Operating cash flow exceeded net income: passed
- ✓Long-term debt fell relative to assets: passed
- ✗Current ratio improved: not passed
- ✗Share count didn’t rise: not passed
- ✓Gross margin improved: passed
- ✗Asset turnover (revenue ÷ assets) improved: not passed
- −17.2%Last 12 months
Over the last 12 months, China Pharma Holdings lost money: its net loss was 17.2% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −13.1%Last 12 months
Over the last 12 months, China Pharma Holdings’s net loss was 13.1% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About China Pharma Holdings Inc
China Pharma Holdings, Inc. is a specialty pharmaceutical company that develops, manufactures and markets a diversified portfolio of products focused on conditions with a high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective, high-margin business model is driven by market demand and supported by eight scalable GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across all major cities and provinces in China. The Company's wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- China
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- NYSE American
- Asset type
- Common stock
- Price history since
CPHI news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
CPHI stock FAQ
What is CPHI stock’s price today?
China Pharma Holdings (CPHI) traded at $0.57 at the close on , up $0.04 (7.53%) from the previous close of $0.53. Over the past 52 weeks it has traded between $0.38 and $19.19.
If you invested $1,000 in CPHI 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in CPHI on would be worth about $6 at the close on , a total return of −99.4%. The same $1,000 would be worth $2 if invested five years ago, $355 if invested one year ago, and $1 if invested 20 years ago. Past performance doesn’t predict future returns.
What is China Pharma Holdings’s market cap?
China Pharma Holdings’s market capitalization is about $23.1 million. That’s Tiingo’s daily market cap for , at that day’s closing price of $0.57 (how market cap works).
How much revenue does China Pharma Holdings make?
China Pharma Holdings reported $3.9 million of revenue over the four quarters to , down 11.0% from the twelve months before. In its latest quarter (Q2 FY26, ended ) revenue was $948.3 thousand, down 7.5% from a year earlier.
Is China Pharma Holdings profitable?
Not over the four quarters to . China Pharma Holdings reported a net loss of $4.5 million across those four quarters on $3.9 million of revenue.
Does CPHI pay a dividend?
China Pharma Holdings hasn’t paid a dividend in the last twelve months.
What is CPHI’s 52-week high and low?
Over the past 52 weeks CPHI has traded as low as $0.38 and as high as $19.19. At $0.57 at the close on , it is 97.0% below that high and 49.3% above the low.
What is CPHI’s all-time high?
CPHI’s highest closing price was $18,800.00 on , adjusted for stock splits. At $0.57 at the close on , it is 100.0% below that record.
Has CPHI stock ever split?
Yes, four times: 1-for-20 on ; 1-for-10 on ; 1-for-5 on ; 1-for-10 on .
How has CPHI stock performed?
Including dividends and measured to the close on , CPHI has returned −52.9% so far this year and −64.5% over the past year, and −99.8% over five years (−71.6% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is China Pharma Holdings in?
China Pharma Holdings is in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry, and is headquartered in China.
What exchange does CPHI trade on?
China Pharma Holdings trades on the NYSE American under the ticker symbol CPHI. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.